The Heidel Laboratory at the University Hospital Greifswald uses global transcriptome and proteome profiling in combination with in vitro and in vivo CRISPR/Cas9 genome editing approaches to identify molecules responsible for cell competition, cell fate decisions and self-renewal in the development and maintenance of myeloid malignancies. We develop genetically engineered mouse models to validate the functional relevance of signaling molecules, epigenetic and metabolic targets in leukemia and chronic myeloid cancers. To translate our findings into pre-clinical studies we use iPSC-technology and patient-derived xenografts.
Current active work projects include:
-
Identification of genetic vulnerabilities in myeloproliferative neoplasms (MPN)
-
Characterization of signaling pathways in hematopoietic stem cells and leukemia stem cells in vitro and in vivo.
-
Investigation of histone expression and modification as potential therapeutic targets for myeloid cancers.
-
Generation and characterization of genetically engineered mouse models and generation of a patient-derived xenograft program for myeloid malignancies.
-
Proteostasis in the aging hematopoietic system as a potential vulnerability for aging-associated hematologic malignancies.